Alignment Healthcare (NASDAQ:ALHC) Issues Quarterly Earnings Results

Alignment Healthcare (NASDAQ:ALHC) issued its earnings results on Thursday. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03, FiscalAI reports. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same period in the prior year, the business posted ($0.05) earnings per share. The firm’s revenue for the quarter was up 33.3% compared to the same quarter last year.

Here are the key takeaways from Alignment Healthcare’s conference call:

• Membership grew ~31% YoY to 284,800, revenue rose 33% to $1.2B and Adjusted EBITDA increased 88% to $38M — results beat guidance and management raised full‑year revenue and profitability ranges.
• Management highlighted material operational progress — claims auto‑adjudication improved from <15% to >60% YTD — and is investing in AI, contract automation and talent to drive further scale and margin expansion.
• A CMS rule change exposed an internal workflow error that caused the company to pay acute rates instead of observation in January (about a $2M impact that cannot be clawed back); the process was corrected by end of February.
• Full‑year and Q2 guidance incorporate higher inpatient admissions per 1,000 driven by intentional growth in higher‑acuity D‑SNP/LIS/dual members and a cautious risk‑adjustment stance for new members, with potential upside from later CMS “sweeps.”

Alignment Healthcare Price Performance

Shares of NASDAQ ALHC traded up $0.82 on Thursday, hitting $22.54. The company’s stock had a trading volume of 5,274,110 shares, compared to its average volume of 3,307,599. Alignment Healthcare has a 12-month low of $11.63 and a 12-month high of $23.87. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -2,251.75, a price-to-earnings-growth ratio of 4.46 and a beta of 1.20. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71. The stock has a 50 day moving average of $19.38 and a 200-day moving average of $19.42.

Analyst Upgrades and Downgrades

ALHC has been the topic of several recent analyst reports. UBS Group upped their target price on shares of Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 14th. JPMorgan Chase & Co. upped their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. KeyCorp restated an “overweight” rating and set a $28.00 target price on shares of Alignment Healthcare in a research report on Thursday, January 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Monday, April 20th. Finally, Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a research report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Insider Buying and Selling

In other Alignment Healthcare news, President Dawn Christine Maroney sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $20.87, for a total value of $626,100.00. Following the sale, the president owned 1,028,813 shares of the company’s stock, valued at $21,471,327.31. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andreas P. Wagner sold 11,602 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $18.22, for a total transaction of $211,388.44. Following the completion of the sale, the insider directly owned 148,628 shares in the company, valued at $2,708,002.16. This trade represents a 7.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,474,097 shares of company stock valued at $28,679,550. 7.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alignment Healthcare

Several institutional investors and hedge funds have recently modified their holdings of ALHC. Summit Securities Group LLC purchased a new position in shares of Alignment Healthcare during the fourth quarter valued at approximately $26,000. Larson Financial Group LLC purchased a new position in shares of Alignment Healthcare during the third quarter valued at approximately $33,000. Parallel Advisors LLC lifted its stake in shares of Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after buying an additional 773 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Alignment Healthcare during the third quarter valued at approximately $53,000. Finally, Wexford Capital LP acquired a new position in Alignment Healthcare during the third quarter worth approximately $164,000. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Key Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q1 2026 results beat estimates — EPS $0.05 vs. $0.02 expected and revenue $1.24B vs. $1.22B consensus; management highlighted disciplined growth and margin expansion, a direct catalyst for the stock move. Q1 Press Release
• Positive Sentiment: Zacks upgraded ALHC from “hold” to “strong-buy,” which can attract momentum and buy-side interest following the earnings beat. Zacks Upgrade
• Positive Sentiment: Technical analysts point to a bullish pennant and breakout potential into prior highs, offering a short-term technical tailwind for traders. FXEmpire Technical Note
• Neutral Sentiment: Management updated Q2 2026 revenue guidance to ~$1.3B and FY2026 revenue guidance to ~$5.2B — both essentially in line with consensus — but EPS guidance was not provided in the update, leaving some earnings visibility unresolved. GlobeNewswire Release
• Neutral Sentiment: Pre-earnings coverage and sector pieces provided context but no new fundamentals; useful for framing but unlikely to move the stock materially beyond the results and upgrade. Earnings Preview
• Negative Sentiment: Despite the beat, the company remains close to break-even profitability: reported a slightly negative net margin (-0.02%) and negative return on equity (~-0.49%) in the quarter, which could cap upside if sustainable margin improvement is uncertain. Q1 Press Release (details)

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.